Pheon Therapeutics
A UK-based biotech developing a pipeline of monotherapies for novel targets and/or with novel payloads.
Pheon’s lead program is a first-in-class antibody drug conjugate (ADC) against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.
The company is backed by healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies.
In September 2022, the company laucnhed with $68 million in Series A financing.
Latest Pheon Therapeutics News & Features
10 October 2023
5 July 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze